Department of Infectious Diseases and Clinical Microbiology, Kırıkkale University Faculty of Medicine, Kırıkkale.
Department of Microbiology Reference Laboratories and Biological Products, Ministry of Health, General Directorate of Public Health, Ankara, Turkey.
Turk J Pediatr. 2021;63(6):1020-1027. doi: 10.24953/turkjped.2021.06.010.
Pertussis caused by Bordetella pertussis, is a disease leading to significant morbidity and mortality in neonates and infants. Direct protection of the infant may be achieved by maternal and neonatal vaccination. Despite primary vaccination, infants under six months pose the greatest risk of infection with pertussis. Maternal immunization provides a high level of infant protection from birth until immunity is achieved by active vaccination. There is no routine Tdap vaccination recommendation for pregnant women in Turkey. This study was carried out to determine pertussis antibody levels in pregnant women and provide data for improving vaccine planning.
The study was carried out with 133 pregnant women in Turkey. Antibody titers to pertussis toxin (anti-PT) and filamentous hemagglutinin (anti-FHA) were measured by the commercially available ELISA.
Among 133 participants, 93 (69.9%) were found to be immune according to anti-PT IgG antibody levels. According to anti-FHA IgG antibody levels, 123 (92.5%) participants were considered to be immune. A positive correlation was observed between PT and FHA and the findings were statistically significant (P < 0.001, r = 0.343). In the study group, the ages of the participants varied between 17 and 44 years. The mean age of those who were immune was 27.3±5.6, the mean age of non-immune patients was 29.1±6.2 and the difference was not statistically significant (P= 0.14).
Our results reveal that approximately one-third of pregnant women were not immune to pertussis, reflecting many young infants to be vulnerable to pertussis infection until the onset of primary vaccinations, although childhood pertussis vaccination coverage has been high for a long time. We conclude that Tdap vaccine recommendation for pregnant women regardless of previous immunization history may be beneficial for the protection of infants in their first six months.
由百日咳博德特氏菌引起的百日咳是一种导致新生儿和婴儿发病率和死亡率显著的疾病。通过母亲和新生儿接种疫苗可以直接保护婴儿。尽管进行了初级接种,但六个月以下的婴儿感染百日咳的风险最大。母体免疫为婴儿提供了从出生到通过主动疫苗接种获得免疫力的高水平保护。土耳其没有为孕妇接种 Tdap 疫苗的常规建议。本研究旨在确定孕妇的百日咳抗体水平,并为改善疫苗规划提供数据。
本研究在土耳其对 133 名孕妇进行了研究。通过商业上可用的 ELISA 测定百日咳毒素(抗-PT)和丝状血凝素(抗-FHA)的抗体滴度。
在 133 名参与者中,根据抗-PT IgG 抗体水平,有 93 名(69.9%)被认为具有免疫力。根据抗-FHA IgG 抗体水平,有 123 名(92.5%)参与者被认为具有免疫力。PT 和 FHA 之间存在正相关,且相关性具有统计学意义(P<0.001,r=0.343)。在研究组中,参与者的年龄在 17 至 44 岁之间。具有免疫力的参与者的平均年龄为 27.3±5.6 岁,无免疫力的参与者的平均年龄为 29.1±6.2 岁,差异无统计学意义(P=0.14)。
我们的结果表明,约三分之一的孕妇对百日咳没有免疫力,这反映出尽管儿童百日咳疫苗接种覆盖率长期以来一直很高,但许多年幼的婴儿在开始进行初级接种之前容易感染百日咳。我们得出结论,无论先前的免疫史如何,建议孕妇接种 Tdap 疫苗可能有助于保护婴儿在出生后的头六个月免受感染。